Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords



Advances in machine learning for tumour classification in cancer of unknown primary: A mini-review
Indexado
WoS WOS:001373330100001
Scopus SCOPUS_ID:85210657030
DOI 10.1016/J.CANLET.2024.217348
Año 2025
Tipo revisión

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras


Abstract



Cancers of unknown primary (CUP) are a heterogeneous group of aggressive metastatic cancers where standardised diagnostic techniques fail to identify the organ where it originated, resulting in a poor prognosis and resistance to treatment. Recent advances in large-scale sequencing techniques have enabled the identification of mutational signatures specific to particular tumour subtypes, even from liquid biopsy samples such as blood. This breakthrough paves the way for the development of new cost-effective diagnostic strategies. This mini-review explores recent advancements in Machine Learning (ML) and its application to tumour classification methods for CUP patients, identifying its weaknesses and strengths when classifying the tumour type. In the era of multiomics, integrating several sources of information (e.g., imaging, molecular biomarkers, and family history) requires important theoretical advancements: increasing the dimensionality of the problem can result in lowering the predictive accuracy and robustness when data is scarce. Here, we review and discuss different architectures and strategies for incorporating cutting-edge machine learning into CUP diagnosis, aiming to bridge the gap between theory and clinical practice.

Revista



Revista ISSN
Cancer Letters 0304-3835

Métricas Externas



PlumX Altmetric Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Disciplinas de Investigación



WOS
Oncology
Scopus
Oncology
Cancer Research
SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional



Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.


Autores - Afiliación



Ord. Autor Género Institución - País
1 OROSTICA-TAPIA, KAREN YASMIN Mujer Universidad de Talca - Chile
2 Mardones, Felipe - Universidad de Talca - Chile
3 BERNAL-GOMEZ, YANARA ALEJANDRA - Fac Med Clin Alemana Univ Desarrollo - Chile
Facultad de Medicina Clínica Alemana Universidad del Desarrollo - Chile
4 Molina, Samuel - Universidad de Chile - Chile
5 ORCHARD-CONCHA, MARCOS EDUARDO Hombre Universidad del Desarrollo - Chile
Universidad de Chile - Chile
6 VERDUGO-SALGADO, RICARDO ALEJANDRO Hombre Universidad de Chile - Chile
Universidad de Talca - Chile
7 Carvajal-Hausdorf, Daniel E. Hombre Universidad del Desarrollo - Chile
8 MARCELAIN-CUBILLOS, KATHERINE JENNY Mujer Universidad de Chile - Chile
9 Contreras, Seba Hombre Max Planck Inst Dynam & Selforg - Alemania
Max Planck Institute for Dynamics and Self-Organization - Alemania
10 ARMISEN-YANEZ, RICARDO AMADO Hombre Fac Med Clin Alemana Univ Desarrollo - Chile
Facultad de Medicina Clínica Alemana Universidad del Desarrollo - Chile

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Financiamiento



Fuente
Fondo Nacional de Desarrollo Científico y Tecnológico
Universidad de Talca
Max-Planck-Society
Roche
Proyecto Anillo en Ciencia y Tecnologia
Agencia Nacional de Investigación y Desarrollo
Janssen & Tecnofarma

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos



Agradecimiento
Open Access funding enabled and organized by Projekt DEAL. This work received support from Agencia Nacional de Investigacion y Desarrollo (ANID) , Chile, through projects Fondecyt Iniciacion 11241185 (KO) , Proyecto Anillo en Ciencia y Tecnologia ACT210079 (RA) and FONDECYT regular 1221436 (RA) and from the IPIG-ACA-KaOr Fund financed by the Gender Equality Instrument of the University of Talca, InES-Gender Project INGE210025 (ANID) (KO) . YABreceived support from ANID, Chile, through Becas Doctorado Nacional 2021- no 21210439. SC received support from the Max-Planck-Society. The funding sources were not involved in the study design, collection, analysis, and interpretation of data; in the writing of report, nor in the decision to submit the article for publication.r received support from ANID, Chile, through Becas Doctorado Nacional 2021- no 21210439. SC received support from the Max-Planck-Society. The <B>Funding</B> sources were not involved in the study design, collection, analysis, and interpretation of data; in the writing of report, nor in the decision to submit the article for publication.
Open Access funding enabled and organized by Projekt DEAL. This work received support from Agencia Nacional de Investigaci\u00F3n y Desarrollo (ANID), Chile, through projects Fondecyt Iniciaci\u00F3n 11241185 (KO), Proyecto Anillo en Ciencia y Tecnolog\u00EDa ACT210079 (RA) and FONDECYT regular 1221436 (RA) and from the IPIG-ACA-KaOr Fund financed by the Gender Equality Instrument of the University of Talca, InES-Gender Project INGE210025 (ANID)(KO). YAB received support from ANID, Chile, through Becas Doctorado Nacional 2021\u2013 no 21210439. SC received support from the Max-Planck-Society.RA declares honoraria for conferences, advisory boards, and educational activities from Roche, grants, and support for scientific research from Illumina, Pfizer, Roche & Thermo Fisher Scientific, and honoraria for conferences from Thermo Fisher Scientific, Janssen & Tecnofarma and is an Illumina, Thermo Fisher Scientific, Moderna and Pfizer stock holder.
Open Access funding enabled and organized by Projekt DEAL. This work received support from Agencia Nacional de Investigaci\u00F3n y Desarrollo (ANID), Chile, through projects Fondecyt Iniciaci\u00F3n 11241185 (KO), Proyecto Anillo en Ciencia y Tecnolog\u00EDa ACT210079 (RA) and FONDECYT regular 1221436 (RA) and from the IPIG-ACA-KaOr Fund financed by the Gender Equality Instrument of the University of Talca, InES-Gender Project INGE210025 (ANID)(KO). YAB received support from ANID, Chile, through Becas Doctorado Nacional 2021\u2013 no 21210439. SC received support from the Max-Planck-Society.RA declares honoraria for conferences, advisory boards, and educational activities from Roche, grants, and support for scientific research from Illumina, Pfizer, Roche & Thermo Fisher Scientific, and honoraria for conferences from Thermo Fisher Scientific, Janssen & Tecnofarma and is an Illumina, Thermo Fisher Scientific, Moderna and Pfizer stock holder.

Muestra la fuente de financiamiento declarada en la publicación.